This review highlights the significant cardiovascular side effects of Cyclosporin A, including hypertension and metabolic disturbances, alongside its effects on cardiac hypertrophy and myxoma cells.
Alerts clinicians to cyclosporin A cardiometabolic risks post-transplant; leaves open its myxoma cytokine effects for targeted study.
Cyclosporin A (CsA) is now routinely used for transplantation of all solid organs, bone marrow transplantation, and for an increasing number of immunological diseases. However, treatment with CsA is an important iatrogenic cause of post-transplant hypertension, hyperlipidemia, and diabetes, which may contribute to the high cardiovascular morbidity in transplant recipients. Recently, the calcineurin inhibitor CsA has been employed in vivo and in vitro to examine the role of calcineurin in the signal transduction leading to cardiac hypertrophy. A cell culture study demonstrated the inhibitory effect of CsA on cytokine production by cardiac myxoma cells, the most common primary tumor of the heart. This review discusses recent data on the cardiovascular effects of CsA.
No takes yet. Share an insight, caveat, or question.
Sakamoto et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: